Rezolute (NASDAQ:RZLT – Get Free Report) was downgraded by stock analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a report released on Thursday,Zacks.com reports.
Other analysts also recently issued research reports about the stock. Wall Street Zen downgraded shares of Rezolute from a “hold” rating to a “sell” rating in a research report on Tuesday, June 30th. Guggenheim boosted their price objective on shares of Rezolute from $6.00 to $11.00 and gave the company a “buy” rating in a report on Monday, June 15th. Citizens Jmp raised Rezolute from a “market perform” rating to an “outperform” rating and set a $11.00 target price on the stock in a research report on Wednesday, June 3rd. Maxim Group lifted their price target on Rezolute from $10.00 to $14.00 and gave the stock a “buy” rating in a research report on Tuesday, June 2nd. Finally, Wedbush boosted their price target on Rezolute from $5.00 to $6.00 and gave the company an “outperform” rating in a research note on Wednesday, June 3rd. Eight equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $9.38.
View Our Latest Research Report on Rezolute
Rezolute Stock Up 5.5%
Rezolute (NASDAQ:RZLT – Get Free Report) last issued its quarterly earnings data on Tuesday, May 12th. The company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.17) by $0.01. On average, sell-side analysts expect that Rezolute will post -0.69 EPS for the current year.
Institutional Investors Weigh In On Rezolute
Hedge funds and other institutional investors have recently made changes to their positions in the company. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Rezolute during the 4th quarter valued at about $494,000. Knott David M Jr boosted its stake in shares of Rezolute by 8.8% in the first quarter. Knott David M Jr now owns 370,000 shares of the company’s stock worth $1,128,000 after acquiring an additional 30,000 shares during the last quarter. AlphaCentric Advisors LLC increased its position in shares of Rezolute by 6.2% during the first quarter. AlphaCentric Advisors LLC now owns 71,227 shares of the company’s stock worth $217,000 after purchasing an additional 4,171 shares in the last quarter. Jennison Associates LLC purchased a new stake in shares of Rezolute during the first quarter worth approximately $10,489,000. Finally, Y Intercept Hong Kong Ltd acquired a new stake in Rezolute during the 1st quarter worth $90,000. Institutional investors and hedge funds own 82.97% of the company’s stock.
Rezolute Company Profile
Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema.
Further Reading
- Five stocks we like better than Rezolute
- MarketBeat Week in Review – 07/13- 07/17
- AST SpaceMobile Stock Sinks as SpaceX Fallout Rattles Space Sector
- Aehr Test Systems Stock Soars on Earnings, Eyes Over 150% Revenue Growth
- TSMC Just Gave AI Chip Bulls Another Reason to Stay Confident
Receive News & Ratings for Rezolute Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rezolute and related companies with MarketBeat.com's FREE daily email newsletter.
